Vivacelle Bio to Participate in BIO Partnering @ JPM Week 2025
Vivacelle Bio to Participate in BIO Partnering @ JPM Week 2025
KANSAS CITY, Mo., Jan. 9, 2025 /PRNewswire/ -- Vivacelle Bio, a late-stage biopharma company developing life-saving treatments for shock and trauma, today announced its participation in BIO Partnering @ JPM Week 2025 in San Francisco January 13-16.
密蘇里州堪薩斯城，2025年1月9日 /PRNewswire/ -- Vivacelle Bio是一家處於後期階段的生物製藥公司，致力於開發用於治療休克和創傷的救命療法，今天宣佈參加2025年1月13日至16日在舊金山舉行的BIO Partnering @ JPm Week 2025。
Details of the event:
活動詳情：
|
Event: |
BIO Partnering @ JPM Week 2025 |
|
Date and Time: |
January 13-16, 2025 |
|
Location: |
San Francisco Marriott Marquis & Virtual |
|
Registration: |
|
事件： |
BIO Partnering @ JPm Week 2025 |
|
日期和時間： |
2025年1月13日至16日 |
|
地點: |
舊金山萬麗大酒店及虛擬會議 |
|
註冊： |
During the event, members of Vivacelle's management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development strategy, recent corporate achievements, and anticipated milestones.
在活動期間，Vivacelle管理團隊的成員將與註冊投資者和潛在合作伙伴進行一對一會議，展示公司的業務和臨牀發展策略、近期的企業成就以及預期的里程碑。
About Vivacelle Bio
Vivacelle Bio is a late-stage biopharma company developing life-saving treatments for shock and trauma. The company's lead, Phase 3 product, VBI-S, is built on its pioneering and patented phospholipid nanoparticle technology, which leverages the redistribution of nitric oxide to treat multisystem organ failure and elevate blood pressure in hypovolemic septic shock, a leading cause of death that impacts millions around the world. A Phase 2 trial of VBI-S demonstrated 100% efficacy, with the treatment resulting in elevated blood pressure in hypovolemic septic shock patients who are refractory to therapy and markedly improved organ dysfunction. In addition to venture capital, Vivacelle has garnered backing and financial support from the US Department of Defense and the National Institutes of Health. Vivacelle Bio is headquartered in Kansas City, MO. Learn more at .
關於Vivacelle Bio
Vivacelle Bio是一家晚期生物製藥公司，開發拯救生命的休克和創傷治療方案。該公司的主打產品VBI-S目前處於3期階段，基於其開創性和專利的磷脂納米粒子技術，利用一氧化氮的再分配來治療多系統器官衰竭，並提高在低血容量膿毒性休克中患者的血壓，這是一種影響全球數百萬人的主要死亡原因。VBI-S的2期臨牀試驗顯示出100%的有效性，該治療在對治療無反應的低血容量膿毒性休克患者中有效提高了血壓，並顯著改善了器官功能障礙。除了創投外，Vivacelle還得到了美國國防部和國家衛生研究院的支持和財務支持。Vivacelle Bio總部位於密蘇里州堪薩斯城。了解更多信息請訪問。
The company's Phase 3 study is funded by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) program via the Medical Technology Enterprise Consortium (MTEC).
公司的3期研究由海軍醫學研究指揮部（NMRC）通過醫療技術企業聯盟（MTEC）的海軍先進醫療發展（NAMD）項目資助。
About MTEC
The Medical Technology Enterprise Consortium (MTEC) is a 501(c)(3) biomedical technology consortium collaborating under an Other Transaction Agreement (OTA) with the U.S. Army Medical Research and Development Command (USAMRDC) that serves those who serve our nation. For more information about MTEC, visit mtec-sc.org.
關於MTEC
醫療技術企業聯盟（MTEC）是一個501(c)(3)的生物醫學技術聯盟，根據與美國陸軍醫學研究與發展指揮部（USAMRDC）的其他交易協議（OTA）進行合作，服務於那些爲國家服務的人。有關MTEC的更多信息，請訪問mtec-sc.org。
The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government.
此處包含的觀點和結論僅代表作者個人觀點，不應被解讀爲美國政府的官方政策或背書，無論是明示還是暗含。
Contact
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
[email protected]
聯繫
投資者關係
提伯倫戰略顧問公司
大衛·愛爾蘭
(231) 632-0002
[email protected]
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
[email protected]
媒體關係
提伯倫戰略顧問公司
凱西·麥克唐納
(646) 577-8520
[email protected]
SOURCE Vivacelle Bio
來源：Vivacelle Bio
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想讓貴公司的資訊在PRNEWSWIRE.COM上特色展示嗎？
譯文內容由第三人軟體翻譯。
